2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial — Sebastian Bauer (2025) | RDL Network
2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial
H. Gelderblom, Vivek A. Bhadri, S. Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Meike van de Sande, Nicholas M. Bernthal, Albiruni Ryan Abdul Razak, A. Italiano, M. Ahmed, Axel Le Cesne, Christopher Tait, A. Saunders, B. Harrow, Manu Sharma, R. Ruiz-Soto, M.L. Sherman, Jean Yves Blay, W.D. Tap
Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap
William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom
Jean Yves Blay, H. Gelderblom, P. Rutkowski, A. Wagner, Meike van de Sande, A. Falcon Gonzalez, S. Stacchiotti, A. Le Cesne, T. Alcindor, C. Serrano, E. Palmerini, Vishnu Ravi, A. Casado Herráez, B. Seddon, Michael F. Vallee, R. Jarecha, M. Sharma, R. Ruiz-Soto, M.L. Sherman, W.D. Tap
C. Serrano, Jean Yves Blay, P. Rutkowski, Hans Gelderblom, S. Stacchiotti, A. Falcon Gonzalez, Janak Desai, A. Le Cesne, Virginia Ferraresi, E. Palmerini, Breelyn A. Wilky, Andrew J. Wagner, Nicholas M. Bernthal, Michiel A. J. van de Sande, Supraja Narasimhan, B. Harrow, Manu Sharma, R. Ruiz-Soto, M.L. Sherman, W.D. Tap
Discussion(0)
No comments yet. Be the first to comment.